Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

22.49

Margin Of Safety %

Put/Call OI Ratio

2.22

EPS Next Q Diff

-0.12

EPS Last/This Y

1.19

EPS This/Next Y

1.44

Price

46.57

Target Price

66.11

Analyst Recom

1.3

Performance Q

23.76

Relative Volume

0.47

Beta

1.03

Ticker: TARS




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-12-19TARS51.961.960.075919
2024-12-20TARS52.911.890.426003
2024-12-23TARS54.361.894.804827
2024-12-24TARS54.041.900.084853
2024-12-26TARS54.271.930.004824
2024-12-27TARS55.051.931.004830
2024-12-30TARS54.721.920.374860
2024-12-31TARS55.391.880.464922
2025-01-02TARS55.111.860.944959
2025-01-03TARS55.421.840.075097
2025-01-06TARS56.231.850.195096
2025-01-07TARS55.031.810.245141
2025-01-08TARS55.191.807.005160
2025-01-09TARS55.241.807.005160
2025-01-10TARS52.641.811.135191
2025-01-13TARS46.981.810.025240
2025-01-14TARS44.341.950.135115
2025-01-15TARS46.572.221.004936
2025-01-16TARS46.822.210.154955
2025-01-17TARS46.592.220.014912
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-12-19TARS51.9624.9- -3.43
2024-12-20TARS52.9024.9- -3.43
2024-12-23TARS54.4124.9- -3.43
2024-12-24TARS54.0424.9- -3.43
2024-12-26TARS54.3524.9- -3.43
2024-12-27TARS54.9924.9- -3.43
2024-12-30TARS54.7124.9- -3.43
2024-12-31TARS55.3424.9- -3.43
2025-01-02TARS55.1224.9- -3.43
2025-01-03TARS55.5824.9- -3.43
2025-01-06TARS56.2024.9- -3.43
2025-01-07TARS55.0324.9- -3.43
2025-01-08TARS55.2424.9- -3.43
2025-01-09TARS55.2424.9- -3.43
2025-01-10TARS52.6024.9- -3.43
2025-01-13TARS47.0524.9- -3.43
2025-01-14TARS44.3524.9- -3.43
2025-01-15TARS46.5624.9- -3.43
2025-01-16TARS46.9124.9- -3.43
2025-01-17TARS46.5734.4- -3.43
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-12-19TARS-0.8012.1022.04
2024-12-20TARS-0.8012.1022.04
2024-12-23TARS-0.6112.1022.04
2024-12-24TARS-0.6112.1022.04
2024-12-26TARS-0.6212.1023.15
2024-12-27TARS-0.6212.1023.15
2024-12-30TARS-0.6111.9923.15
2024-12-31TARS-0.6111.9923.15
2025-01-02TARS-0.6111.9923.15
2025-01-03TARS-0.6211.9923.15
2025-01-06TARS-0.6111.8323.15
2025-01-07TARS-0.6111.8323.15
2025-01-08TARS-0.6211.8323.15
2025-01-09TARS-0.6211.8323.15
2025-01-10TARS-0.6211.8323.15
2025-01-13TARS-0.6212.1422.49
2025-01-14TARS-0.6212.1422.49
2025-01-15TARS-0.6212.1422.49
2025-01-16TARS-0.6212.1422.49
2025-01-17TARS-0.6212.1422.49
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.61

Avg. EPS Est. Current Quarter

-0.98

Avg. EPS Est. Next Quarter

-0.73

Insider Transactions

-0.62

Institutional Transactions

12.14

Beta

1.03

Average Sales Estimate Current Quarter

57

Average Sales Estimate Next Quarter

62

Fair Value

Quality Score

43

Growth Score

56

Sentiment Score

56

Actual DrawDown %

26.9

Max Drawdown 5-Year %

Target Price

66.11

P/E

Forward P/E

PEG

P/S

13.72

P/B

7.48

P/Free Cash Flow

EPS

-3.81

Average EPS Est. Cur. Y​

-3.43

EPS Next Y. (Est.)

-1.99

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-103.64

Relative Volume

0.47

Return on Equity vs Sector %

-75.6

Return on Equity vs Industry %

-63.1

EPS 1 7Days Diff

0.5

EPS 1 30Days Diff

0.52

EBIT Estimation

Tarsus Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 244
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
stock quote shares TARS – Tarsus Pharmaceuticals Inc Stock Price stock today
news today TARS – Tarsus Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch TARS – Tarsus Pharmaceuticals Inc yahoo finance google finance
stock history TARS – Tarsus Pharmaceuticals Inc invest stock market
stock prices TARS premarket after hours
ticker TARS fair value insiders trading